Abstract:Background: Current first-line anti-proteinuric treatments do not produce a satisfactory therapeutic effect in a considerable number of patients with nephrotic syndrome (NS). Interest in adrenocorticotropic hormone (ACTH) for the treatment of NS has recently been revived. The present study investigated the efficacy and safety of ACTH treatment in children with frequent relapsing NS (FRNS), steroid-dependent NS (SDNS), and steroid-resistant NS (SRNS). Method: The ACTH treatment group was comprised of NS patients receiving ACTH treatment. Patients with serum cortisol concentrations <85.3 nmol/L and who had not received ACTH treatment previously were enrolled in the control group from January 2018 to January 2021. The maintenance dose of prednisone, the number of disease recurrences, the time of first disease relapse, immunosuppressant use, serum cortisol levels, and adverse events were recorded in both groups. Results: Fifty-one patients were included in the ACTH group, and twenty-one patients were enrolled in the control group. Concurrent treatment with one or more immunosuppressive and/or cytotoxic treatments occurred in 92.2% and 85.7% of patients in the ACTH and control groups, respectively, throughout the study period. A greater reduction in the prednisone maintenance dose was observed in the ACTH group compared with the control group after 1 year of follow up (0.603 ± 0.445 mg/kg vs. 0.267 ± 0.500 mg/kg, p = 0.006). During the one-year study period, fewer participants experienced one or more disease relapses in the ACTH group (45.1%) compared to the control group (76.2%, odds ratio = 3.896, p = 0.016). The number of disease recurrences per patient in the ACTH group was less than that in the control group (median difference = −1, p = 0.006). The mean length of remission was 8.902 m and 7.905 m in the ACTH group and control group, respectively. A log-rank test showed a longer relapse free survival for patients in the ACTH group ( p = 0.046), but the Breslow test showed no significant difference between groups ( p = 0.104). Ten patients in the ACTH group successfully discontinued all drug therapies. No patients in the control group were able to discontinue drug therapy as of February 2022. Conclusion: ACTH, combined with multiple drugs, is effective at reducing the prednisone maintenance dose and may effectively prevent disease relapses in childhood NS.

Effect of Tripterygium Glycosides Combined with Hormones on Adult NS Glucocorticoid Resistance and HSP90

Clinical Characteristics and Prognostic Factors of Nephrotic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation

Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.

Tripterygium therapy in primary nephrotic syndrome

Effects of Steroids-Free Immunosuppressive Treatment for Membranous Nephropathy Combining with Type 2 Diabetes Mellitus

Enhanced Steroid Therapy In Adult Minimal Change Nephrotic Syndrome: A Systematic Review And Meta-Analysis

The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schönlein purpura nephritis.

Comparison of Tripterygium Wilfordii Multiglycosides and Tacrolimus in the Treatment of Idiopathic Membranous Nephropathy: a Prospective Cohort Study

Tacrolimus As a Steroid-Sparing Agent for Adults with Steroid-Dependent Minimal Change Nephrotic Syndrome

Efficacy and Safety of Glucocorticoids Therapy for IgA Nephropathy: a Meta-Analysis of Randomized Controlled Trials.

Protopanaxadiol synergizes with glucocorticoids to enhance the therapeutic effect in adriamycin-induced nephrotic syndrome

Tripterygium glycosides improve abnormal lipid deposition in nephrotic syndrome rat models

Mycophenolate mofetil combined with low dose prednisone in the treatment for adults with minimal change nephrotic syndrome and concomitant HBsAg positive

Efficacy of Ginsenosides Combined with Prednisone in Patients with Systemic Lupus Erythematosus: a Prospective, Randomized, Double-Blind, Placebo-Controlled Trial

A prospective randomly controlled clinical trial on azithromycin therapy for induction treatment of children with nephrotic syndrome

The analysis of low-dose glucocorticoid maintenance therapy in patients with primary nephrotic syndrome suffering from COVID-19

The Efficacy and Safety of Tacrolimus Monotherapy in Adult-Onset Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy

Prednisone Combined with Tripterygium Glycosides in the Treatment of Membranous Lupus Nephropathy

Real-word adrenocorticotropic hormone treatment for childhood-onset nephrotic syndrome

Comparison of the efficacy of steroid-free versus classic steroid-containing regimens in primary membranous nephropathy

Clinical Observation of Dihuangye Total Glycoside Capsule Combined with Benazepril Hydrochloride Tablets on Henoch-Schonlein Purpura Nephritis in 60 Children